Recent News

By Category: Countermeasures

Bird vaccine for West Nile Virus

(ScienceDaily) University of British Columbia researchers have developed a vaccine that may halt the spread of West Nile Virus (WNV) among common and endangered bird species.WNV, a mosquito borne pathogen, arrived in North America in 1999 and is now endemic across the continent. In 2012 alone, WNV killed 286 people in the United States, and Read More »

July 10, 2013
| Filed under North America, Countermeasures, and Research
Share

Antibiotic from the Sea is Effective Against Anthrax

(LaboratoryEquipment) A new potential drug from a marine microorganism is effective against anthrax and various other Gram-positive bacteria, as reported by American scientists in the journal Angewandte Chemie. A chlorinated analogue kills off Gram-negative bacteria. Anthrax is a dangerous infectious disease caused by the spore-forming bacterium Bacillus anthracis and transmitted by infected farm animals. For Read More »

July 3, 2013
| Filed under North America, Countermeasures, and Research
Share

Antibiotics: Change route of delivery to mitigate resistance

(EurekAlert) New research suggests that the rapid rise of antibiotic resistance correlates with oral ingestion of antibiotics, raising the possibility that other routes of administration could reduce the spread of resistance. The manuscript appears online ahead of print in the journal Antimicrobial Agents and Chemotherapy. “For more than 40 years, a few doses of penicillin Read More »

June 27, 2013
| Filed under North America, Countermeasures, and Research
Share

Researchers strike gold with nanotech vaccine

(ScienceDaily) Scientists in the US have developed a novel vaccination method that uses tiny gold particles to mimic a virus and carry specific proteins to the body’s specialist immune cells. The technique differs from the traditional approach of using dead or inactive viruses as a vaccine and was demonstrated in the lab using a specific Read More »

June 26, 2013
| Filed under North America, Countermeasures, and Research
Share

Basilea awarded contract by BARDA of up to USD 89 million for the development of its novel antibiotic BAL30072

(MarketWired) BAL30072 current multiple ascending dose study reached maximum tolerated dose Further development, including combination studies with carbapenems, planned under BARDA agreement Basel, Switzerland, June 25, 2013 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the Biomedical Advanced Research and Development Authority (BARDA), a division within the U.S. Department of Health and Human Services, Read More »